Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS

Approximately 30% of human cancers harbor a gain‐in‐function mutation in the RAS gene, resulting in constitutive activation of the RAS protein to stimulate downstream signaling, including the RAS‐mitogen activated protein kinase pathway that drives cancer cells to proliferate and metastasize. RAS‐dr...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:MedComm (2020)
Glavni autori: Ward, Antonio B., Keeton, Adam B., Chen, Xi, Mattox, Tyler E., Coley, Alex B., Maxuitenko, Yulia Y., Buchsbaum, Donald J., Randall, Troy D., Zhou, Gang, Piazza, Gary A.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Reviews
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7567124/
https://ncbi.nlm.nih.gov/pubmed/33073260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mco2.10
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items